drugset / Trial / NCT01122498

A Safety Study Of BMP-655/ACS As An Adjuvant Therapy For Treatment Of Rotator Cuff Tears

NCT01122498 ↗

Phase 1 Terminated 23 enrolled Pfizer
RandomizedSingle-groupOpen-labelTreatment

Summary

Subjects undergoing an open surgical repair for their torn Rotator Cuff (RC) will be consented, screened, and enrolled in the study if they meet all eligibility criteria. At the time of open surgical repair, subjects who are randomized to receive the test article in addition to the Standard of Care (SOC) will be hospitalized and have a single dose of BMP-655/ACS surgically implanted at the site of tendon attachment to bone. Subjects who are randomized to receive SOC alone will receive no test article. Following surgery, subjects will be prescribed a rehabilitation plan. Subjects will then complete 9 follow-up visits beginning 24 hours after surgery and continuing through 52 weeks.

Timeline

Start
2010-06
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BMP-655/ACS Protein / enzyme biologic 0.015 mg/ml Other
Subject BMP-655/ACS Protein / enzyme biologic 0.025 mg/ml Other
Subject BMP-655/ACS Protein / enzyme biologic 0.05 mg/ml Other
Subject BMP-655/ACS Protein / enzyme biologic 0.15 mg/ml Other

Indications